Development of nanobodies against human Survivin, applicable to suppress cell proliferation.

Abstract

Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is overexpressed in many cancers, making it a valuable target for therapy and a biomarker for cancer diagnostics. As Survivin contributes to cancer development by inhibiting apoptosis and promoting rapid cell division, inhibiting its activity is a promising strategy to overcome cancer resistance to apoptosis and reduce tumor growth. In this study, we developed nanobodies targeting human Survivin using M13 phage display and deep sequencing to identify high-affinity binders. Seven nanobody clones were selected and evaluated through ELISA, western blotting, and immunostaining. Clones 7 and 15, which specifically bind the alpha-helix region of Survivin, effectively suppressed cell proliferation by disrupting cell cycle regulation, likely by interfering interaction with intracellular binding partners. These findings suggest that Survivin-targeting nanobodies hold potential as therapeutic agents for cancer treatment, offering a novel approach to inhibiting tumor growth through the disruption of Survivin-mediated processes.